Epidarex Capital raised $145 million in the first close of its fourth fund as the biotech investor searches for the next generation of standout science in overlooked research corridors of the UK and US. …
Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new


